Lota S. Zoth
CIK: 0001278219
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (14 total)
- Jun 16, 2026ENGN
enGene Therapeutics Inc.
Award(A)DirectStock Option (Right to Buy)
31K shares- - May 20, 2026INO
INOVIO PHARMACEUTICALS, INC.
Award(A)DirectCommon Stock Options
41.8K shares- - May 20, 2026INO
INOVIO PHARMACEUTICALS, INC.
Award(A)DirectRestricted Stock Unit
34.2K shares- - Apr 28, 2026FFIN
FIRST FINANCIAL BANKSHARES INC
Award(A)Direct2.1K shares- - Oct 30, 2025ETNB
89bio, Inc.
Disposition(D)DirectStock Option (Right to Buy)
20K shares- - Oct 30, 2025ETNB
89bio, Inc.
Disposition(D)DirectStock Option (Right to Buy)
25K shares- - Oct 30, 2025ETNB
89bio, Inc.
Disposition(D)DirectStock Option (Right to Buy)
27.4K shares- - Oct 30, 2025ETNB
89bio, Inc.
Disposition(D)DirectStock Option (Right to Buy)
45.2K shares- - Oct 30, 2025ETNB
89bio, Inc.
Disposition(D)DirectStock Option (Right to Buy)
56.4K shares- - Oct 30, 2025ETNB
89bio, Inc.
Disposition(D)DirectStock Option (Right to Buy)
12.5K shares- - Jun 16, 2025ENGN
enGene Holdings Inc.
Award(A)DirectStock Option (Right to Buy)
22.5K shares- - May 21, 2025INO
INOVIO PHARMACEUTICALS, INC.
Exercise(M)Direct2.2K shares- - Feb 3, 2025ETNB
89bio, Inc.
Award(A)DirectStock Option (Right to Buy)
56.4K shares- - Dec 12, 2024(LUMO)
LUMOS PHARMA, INC.
Disposition(D)Direct2.2K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 16, 2026 |  ENGN enGene Therapeutics Inc. | Award(A) Stock Option (Right to Buy) | 31,000 | - | - | Direct |
| May 20, 2026 |  INO INOVIO PHARMACEUTICALS, INC. | Award(A) Common Stock Options | 41,800 | - | - | Direct |
| May 20, 2026 | INO INOVIO PHARMACEUTICALS, INC. | Award(A) Restricted Stock Unit | 34,200 | - | - | Direct |
| Apr 28, 2026 |  FFIN FIRST FINANCIAL BANKSHARES INC | Award(A) | 2,142 | - | $0 | Direct |
| Oct 30, 2025 |  ETNB 89bio, Inc. | Disposition(D) Stock Option (Right to Buy) | 20,000 | - | - | Direct |
| Oct 30, 2025 | ETNB 89bio, Inc. | Disposition(D) Stock Option (Right to Buy) | 25,000 | - | - | Direct |
| Oct 30, 2025 | ETNB 89bio, Inc. | Disposition(D) Stock Option (Right to Buy) | 27,400 | - | - | Direct |
| Oct 30, 2025 | ETNB 89bio, Inc. | Disposition(D) Stock Option (Right to Buy) | 45,150 | - | - | Direct |
| Oct 30, 2025 | ETNB 89bio, Inc. | Disposition(D) Stock Option (Right to Buy) | 56,400 | - | - | Direct |
| Oct 30, 2025 | ETNB 89bio, Inc. | Disposition(D) Stock Option (Right to Buy) | 12,500 | - | - | Direct |
| Jun 16, 2025 | ENGN enGene Holdings Inc. | Award(A) Stock Option (Right to Buy) | 22,500 | - | - | Direct |
| May 21, 2025 | INO INOVIO PHARMACEUTICALS, INC. | Exercise(M) | 2,167 | - | - | Direct |
| Feb 3, 2025 | ETNB 89bio, Inc. | Award(A) Stock Option (Right to Buy) | 56,400 | - | - | Direct |
| Dec 12, 2024 | /logo?size=32) (LUMO) LUMOS PHARMA, INC. | Disposition(D) | 2,187 | - | $0 | Direct |
1-14 of 14 transactions
About Zoth Lota S.
Zoth Lota S. (SEC CIK 0001278219) files insider reports with the SEC as Director of enGene Therapeutics Inc. (ENGN), Director of INOVIO PHARMACEUTICALS, INC. (INO) and Director of FIRST FINANCIAL BANKSHARES INC (FFIN). Signal8 also holds filings tied to 2 other companies.
Signal8 holds 9 ownership filings by Zoth Lota S. (1 Form 3, 8 Form 4), filed between Dec 13, 2024 and Jun 17, 2026. Those filings report 14 transactions, from Dec 12, 2024 to Jun 16, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Zoth Lota S.'s filings is in SAINT-LAURENT.
Recent filings by Zoth Lota S.
- Jun 16, 2026: Grant or award of ENGN derivative securities (Form 4, code A).
- May 20, 2026: Grants or awards of INO derivative securities (2 lines, Form 4, code A).
- Apr 28, 2026: Grant or award of FFIN shares (Form 4, code A).
- Oct 30, 2025: Disposition to issuer transactions of ETNB derivative securities (6 lines, Form 4, code D).
- Jun 16, 2025: Grant or award of ENGN derivative securities (Form 4, code A).
Other insiders filing for enGene Therapeutics Inc. (ENGN)
- Grossman William, Interim Chief Medical Officer
- Chinoporos Constantine, Interim Chief Business Officer
- Richton Kathleen P., SVP, Finance and Treasurer
- Astley-Sparke Philip, Director
- BRUNK GERALD A, Director
- Glickman Richard M, Director